EZH2 and ovarian small cell carcinoma: Histone deacetylase (HDAC) inhibitors and EZH2 inhibitors have been shown to synergize in BRG1-deficient small cell carcinoma of the ovary, hypercalcemic type cells through increased H3K27 acetylation [127].